Respiratory

At the beginning of 2015 we entered a new therapeutic area: respiratory. We started out in the franchise with the drug Tovanor® Breezhaler®, a product that helps patients diagnosed with chronic obstructive pulmonary disease (COPD). Tovanor Breezhaler®, glycopyrronium bromide, is a maintenance bronchodilator treatment for the relief of symptoms in adults with COPD.

This disease affects more than 11 % of the Spanish population and its treatment therefore has a great socio-sanitary impact. According to the WHO, COPD patients are expected to increase in number in the upcoming decades, mainly due to continued exposure to risk factors, and the aging of the population.

In 2022 we launched Bemrist® Breezhaler® and Zimbus® Breezhaler®, two new treatment alternatives for patients with poorly controlled asthma. These fixed-dose combination products in the respiratory area, with good efficacy and safety results from an extensive clinical development program, constitute a convenient treatment for patients given their simple posology compared to existing therapies.